An International Multicenter Retrospective Analysis of RATS, VATS and Open Lung Resections After Neoadjuvant Chemo-immunotherapy
Summary
The study is a retrospective observational study. The study is designed to be multicentric and international and it will analyze medical records from selected patients diagnosed with locally advanced and resectable NSCLC who underwent lung resection by robotic, VATS and open approach after receiving neoadjuvant chemo-immunotherapy. There are no risks for the patients, as this is a retrospective data collection.
Detailed description
The use of neoadjuvant chemo-immunotherapy for the treatment of non-small cell lung cancer (NSCLC) is increasing. However, there is limited research comparing the feasibility and oncologic efficacy of robot-assisted thoracoscopic surgery (RATS), video-assisted thoracoscopic surgery (VATS), and open lung resection, in patients already treated with neoadjuvant chemo-immunotherapy. This study aims to evaluate the benefits of RATS compared to VATS and open surgery in terms of short-term outcomes for patients with NSCLC undergoing neoadjuvant chemo-immunotherapy. All adult patients diagnosed with locally advanced and resectable NSCLC who underwent lung resection from 01-01-2016 to 31-03-2024 by robotic, VATS and open approach after receiving neoadjuvant chemo-immunotherapy will be included. Patients are divided into three groups: robotic lung resection; video-assisted thoracoscopic (VATS) lung resection; open lung resection.
Arms & interventions
Outcome measures
Primary
The perioperative complication of video-assisted thoracoscopic surgery (VATS) approach
The investigators will measure the perioperative complications of VATS approach in patients who received neoadjuvant chemo-immunotherapy. Complications will be categorized according to the Clavien-Dindo scale.
Time frame: 30-90 days after surgery
The perioperative complications of robotic approach
The investigators will measure the perioperative complications of robotic lung resection in patients who received neoadjuvant chemo-immunotherapy. Complications will be categorized according to the Clavien-Dindo scale.
Time frame: from the surgery at 30-90 days after
The perioperative complications of the open approach
The investigators will measure the perioperative complications of open approach in patients who received neoadjuvant chemo-immunotherapy. Complications will be categorized according to the Clavien-Dindo scale.
Time frame: 30-90 days after surgery
Secondary
Duration of surgery
Time frame: from 30 days after surgery
Quality of lymphadenectomy
Time frame: from 30 days after surgery
Conversion rate
Time frame: from 30 days after surgery
Radicality of the resection
Time frame: from 30 days after surgery
Oncological treatment
Time frame: from 30 days after surgery
Survival analysis
Time frame: from 3 to 5 years after surgery
Eligibility criteria
Study locations (3)
Baptist Health South Florida
Miami, Florida, 33176
Memorial Sloan Kettering Cancer Center
New York, New York, 10065
West Virginia University
Morgantown, West Virginia, 26506